Accelerate Diagnostics Company Insiders

Accelerate Diagnostics Management Team Effectiveness

The company has return on total asset (ROA) of (0.7585) % which means that it has lost $0.7585 on every $100 spent on assets. This is way below average. Accelerate Diagnostics' management efficiency ratios could be used to measure how well Accelerate Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 3.25 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (1.87). At this time, Accelerate Diagnostics' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 1.9 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 5.4 M in 2024. Common Stock Shares Outstanding is likely to rise to about 13.1 M in 2024, whereas Net Loss is likely to drop (59.1 M) in 2024.

Accelerate Diagnostics Workforce Comparison

Accelerate Diagnostics Insider Trading

Accelerate Diagnostics Notable Stakeholders

The success or failure of an entity such as Accelerate Diagnostics often depends on how effective the management is. Accelerate Diagnostics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Accelerate management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Accelerate management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Accelerate Diagnostics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Accelerate Diagnostics. Check Accelerate Diagnostics' Beneish M Score to see the likelihood of Accelerate Diagnostics' management manipulating its earnings.

When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.